Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeximod (Rob 803) added to Methotrexate in RA
NCT00525213Phase 2Completed
- Sponsor
- Oxy'Pharm
- Start
- Oct 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of rabeximod in rheumatoid arthritis (RA) (4 arms), sponsored by Oxy'Pharm. Primary endpoint: American College of Rheumatology 20% Improvement Criteria at 12 weeks. Started Oct 2007; status: completed.
02
Drugs
rabeximod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00525213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525213.